GlassScriptPhysician profile
Danielle Spatholt
NPI 1033459151
$12,021.15
in general payments reported to CMS, 2019-2025
23 companies · $7,937 in 2025
The $7,937 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $217 · 2023: $598 · 2024: $2,961 · 2025: $7,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,714 · Travel and Lodging: $1,251 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,714.09 |
| Travel and Lodging | $1,251.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Education | $280.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $2,011.01 | 2025 | Vtama, Hadlima |
| Pfizer INC. | $1,568.00 | 2024-2025 | |
| Abbvie INC. | $978.91 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $923.47 | 2024-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $840.71 | 2023-2025 | |
| Leo Pharma INC. | $744.38 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $739.83 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $698.60 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $651.36 | 2022-2024 | Vtama |
| Ucb, INC. | $543.57 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $512.56 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $507.94 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $435.32 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.01 | 2024-2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $151.02 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $150.84 | 2023-2025 | Opzelura |
| Amgen INC. | $149.19 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $89.27 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.71 | 2025 | Jublia, Cabtreo, Siliq |
| Botanix Sb INC | $29.56 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $18.31 | 2025 | |
| Strata Skin Sciences, INC. | $15.32 | 2025 | Xtrac |
| Janssen Scientific Affairs, LLC | $9.26 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Spatholt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.